The FDA Balancing Act: Can One Agency Simultaneously Protect Youth and Save Adult Smokers?

The Tobacco Control Act of 2009, which gave the FDA authority over tobacco products, established a standard—'appropriate for the protection of public health'—that requires the agency to consider the net population-level impact of its decisions. For reduced-risk products like vaping devices and nicotine pouches, this means weighing the potential benefit to adult smokers (who might use the products to quit or reduce smoking) against the potential harm to youth (who might initiate nicotine use through the products who would not otherwise have used nicotine). The balancing act is structurally difficult: the same product characteristics that make a product appealing to adult smokers (satisfying nicotine delivery, pleasant flavors, user-friendly design) also make it appealing to youth. The same regulatory actions that protect youth (flavor bans, marketing restrictions, product prohibitions) also restrict the availability of the products for adult smokers. The agency is asked to maximize two objectives that are in tension with each other, using blunt regulatory tools, with incomplete data, under intense political pressure from both sides. The FDA's performance of this balancing act is, by any measure, mixed—and the tension between the two sides of the mandate may be unresolvable within the current statutory framework.

The youth-protection side of the FDA's mandate has dominated the agency's public communication and enforcement priorities. The 'youth vaping epidemic' of 2017-2019—when adolescent vaping rates increased dramatically, driven by Juul and other pod-based products—focused the agency's attention on preventing youth initiation. The agency's enforcement actions against Juul (including the 2018 'blitz' on retailers selling to minors, the 2019 warning letter to Juul for unauthorized marketing claims, and the 2022 marketing denial order that was subsequently stayed) were driven primarily by youth-access concerns. The agency's flavor policies—the 2020 guidance prioritizing enforcement against flavored cartridge-based vaping products, and the ongoing consideration of a comprehensive flavor ban—are motivated primarily by the evidence that flavors appeal to youth. The youth-protection side of the mandate is politically popular, publicly visible, and aligned with the broader institutional culture of tobacco control. The FDA's performance on youth protection has been criticized as insufficient by anti-vaping advocates (who want more aggressive action) and as excessive by harm reduction advocates (who argue that the youth-protection measures have restricted adult access to cessation tools). The tension is inherent in the mandate.

The adult-smoker side of the FDA's mandate has been less visible and less prioritized. The agency has authorized 23 vaping products through the PMTA pathway—a process that, by authorizing some products, acknowledges that vaping can be 'appropriate for the protection of public health' for adult smokers. The agency has authorized the marketing of IQOS as a 'modified risk tobacco product,' allowing PMI to communicate that the product reduces exposure to harmful chemicals. The agency has also authorized the marketing of several oral nicotine pouch products. These authorizations represent an institutional acknowledgment that reduced-risk products have a legitimate role in the nicotine market—a position that is in tension with the agency's public communication, which emphasizes the risks of all nicotine products and avoids comparative risk messaging. The adult-smoker side of the mandate is politically less popular (it involves authorizing products from an industry that the public health community views as inherently illegitimate), publicly less visible (product authorizations receive less media attention than enforcement actions), and organizationally challenging (the CTP's expertise is primarily in product regulation, not in smoking-cessation promotion).

The net-effect analysis that the 'appropriate for the protection of public health' standard requires is, in practice, impossible to perform with precision. The FDA must estimate, for each product authorization decision, how many adult smokers will use the product to quit or reduce smoking, how many youth will initiate nicotine use through the product who would not otherwise have used nicotine, and how many smokers will use the product as a complement to smoking (dual use) rather than as a substitute for it. Each of these estimates requires counterfactual modeling—what would have happened in the absence of the product?—that is inherently uncertain and subject to the assumptions of the modeler. The data to inform the estimates is limited, particularly for new product categories where the long-term behavioral trajectories are not yet established. The result is that the net-effect analysis can support a wide range of conclusions, depending on the assumptions that are fed into it—and the choice of assumptions is influenced by the institutional perspective of the analyst. The 'science-based' net-effect analysis that the statute requires is, in practice, a judgment-laden exercise that is shaped by the values and priorities of the institution conducting it.

The structural tension in the FDA's mandate cannot be resolved by better analysis. It can only be resolved by a political decision about the relative weight of youth protection and adult harm reduction—a decision that the statute delegates to the agency but that the agency has not explicitly made. The FDA's decisions suggest a de facto weighting that favors youth protection over adult cessation support: the agency has been more willing to restrict products to protect youth than to authorize products to serve adults. The weighting is politically sustainable—protecting children is a more powerful political narrative than helping adult smokers—but it may not be optimal from a population-health perspective. The modeling studies that have attempted to quantify the tradeoff consistently find that the adult-smoking-cessation benefits of making vaping products widely available outweigh the youth-initiation costs—sometimes by large margins—but the findings depend on assumptions about switching rates, cessation rates, and the counterfactual behavior of smokers and youth in the absence of the products. The modeling is informative but not definitive. The decision about the weight of the two sides of the mandate is, ultimately, a value judgment that the modeling can inform but cannot determine.

The resolution of the FDA's balancing act may require a statutory amendment that clarifies the relative weight of the two sides of the mandate. The 'appropriate for the protection of public health' standard, as currently drafted, treats youth protection and adult cessation as undifferentiated components of a single public health calculus—a framing that obscures the tradeoff rather than clarifying it. A statutory framework that explicitly distinguishes between the two objectives, that requires the agency to quantify the tradeoff when the objectives conflict, and that provides guidance on the relative weight of youth protection versus adult cessation would clarify the agency's decision-making and increase the transparency and accountability of the balancing act. The political feasibility of such an amendment is uncertain—the tobacco control advocacy community would resist any weakening of the youth-protection mandate, and the industry would resist any strengthening of the FDA's authority. But the current framework, which asks the agency to balance incommensurable objectives using imprecise tools, is producing decisions that satisfy no one—and that may be optimizing for political acceptability rather than for population health.

Shareable insight: The FDA's mandate for nicotine regulation pulls the agency in opposite directions: protect youth from all nicotine products, and help adult smokers quit through safer alternatives. The same products serve both populations. The same restrictions affect both. The tension is structural—and the FDA has resolved it, in practice, by prioritizing youth protection over adult cessation. The result is a regulatory framework that may be protecting youth at the cost of adult lives—a tradeoff that has never been explicitly acknowledged or democratically authorized.